Business Description
Tauns Laboratories Inc
ISIN : JP3452250008
Total Employee Number:
446Description
Tauns Laboratories Inc is engaged in development, manufacture and sales of in vitro diagnostics and research reagents and its intermediates in Japan and internationally. The company also offers medical physicochemical measuring equipment, industrial measuring equipment, and medical devices; and contract research services. Its product include Capilia Flu Neo, Capilia Adeno Neo, Capilia, RSV Neo, Capilia hMPV, etc.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.27 | |||||
Equity-to-Asset | 0.39 | |||||
Debt-to-Equity | 1.33 | |||||
Debt-to-EBITDA | 24.43 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 2.14 | |||||
Beneish M-Score | -3.1 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -0.2 | |||||
3-Year EBITDA Growth Rate | -0.5 | |||||
3-Year EPS without NRI Growth Rate | -5.4 | |||||
3-Year FCF Growth Rate | -42.7 | |||||
3-Year Book Growth Rate | 32 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -8.14 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 70.6 | |||||
9-Day RSI | 62.6 | |||||
14-Day RSI | 56.41 | |||||
3-1 Month Momentum % | -2.4 | |||||
6-1 Month Momentum % | -6.15 | |||||
12-1 Month Momentum % | -7.22 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.37 | |||||
Quick Ratio | 0.78 | |||||
Cash Ratio | 0.49 | |||||
Days Inventory | 861.17 | |||||
Days Sales Outstanding | 213.01 | |||||
Days Payable | 151.67 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 5.79 | |||||
Dividend Payout Ratio | 6.76 | |||||
Forward Dividend Yield % | 5.79 | |||||
5-Year Yield-on-Cost % | 5.74 | |||||
3-Year Average Share Buyback Ratio | -1 | |||||
Shareholder Yield % | -8.45 |
Profitability Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 54.21 | |||||
Operating Margin % | -4.51 | |||||
Net Margin % | 7.11 | |||||
EBITDA Margin % | 15.39 | |||||
FCF Margin % | 29.39 | |||||
OCF Margin % | 118.06 | |||||
ROE % | 2.44 | |||||
ROA % | 1.03 | |||||
ROIC % | -0.8 | |||||
3-Year ROIIC % | 0.46 | |||||
ROC (Joel Greenblatt) % | 0.84 | |||||
ROCE % | 0.6 | |||||
Years of Profitability over Past 10-Year | 4 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 120.1 | |||||
Forward PE Ratio | 11.03 | |||||
PE Ratio without NRI | 272.52 | |||||
PS Ratio | 9.01 | |||||
PB Ratio | 3.16 | |||||
Price-to-Tangible-Book | 4.08 | |||||
Price-to-Free-Cash-Flow | 30.58 | |||||
Price-to-Operating-Cash-Flow | 7.61 | |||||
EV-to-EBIT | 388.95 | |||||
EV-to-EBITDA | 75.78 | |||||
EV-to-Revenue | 11.66 | |||||
EV-to-FCF | 39.93 | |||||
Price-to-Graham-Number | 7.03 | |||||
Earnings Yield (Greenblatt) % | 0.26 | |||||
FCF Yield % | 3.3 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Tauns Laboratories Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil 円) | 5,775.393 | ||
| EPS (TTM) (円) | 4.03 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 14.68 | ||
| 14-Day RSI | 56.41 | ||
| 14-Day ATR (円) | 7.272274 | ||
| 20-Day SMA (円) | 474.05 | ||
| 12-1 Month Momentum % | -7.22 | ||
| 52-Week Range (円) | 463 - 603 | ||
| Shares Outstanding (Mil) | 106.45 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Tauns Laboratories Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Tauns Laboratories Inc Stock Events
| Event | Date | Price (円) | ||
|---|---|---|---|---|
| JPY 14.000000 Cash Dividend | 2026-06-29 | 485.00 (-0.82%) | ||
| JPY 14.000000 Cash Dividend | 2025-12-29 | 515.00 (-0.58%) | ||
| JPY 10.000000 Cash Dividend | 2025-06-27 | 560.00 (-2.10%) | ||
| JPY 12.000000 Cash Dividend | 2025-06-27 | 560.00 (-2.10%) | ||
| JPY 6.000000 Cash Dividend | 2024-12-27 | 591.00 (+7.85%) |
Show
Entries
Tauns Laboratories Inc Frequently Asked Questions
What is Tauns Laboratories Inc(TSE:197A)'s stock price today?
The current price of TSE:197A is 円484.00. The 52 week high of TSE:197A is 円603.00 and 52 week low is 円463.00.
When is next earnings date of Tauns Laboratories Inc(TSE:197A)?
The next earnings date of Tauns Laboratories Inc(TSE:197A) is .
Does Tauns Laboratories Inc(TSE:197A) pay dividends? If so, how much?
The Dividend Yield %  of Tauns Laboratories Inc(TSE:197A) is 5.79% (As of Today), Highest Dividend Payout Ratio of Tauns Laboratories Inc(TSE:197A) was 6.76. The lowest was 0.2. And the median was 0.25. The  Forward Dividend Yield % of Tauns Laboratories Inc(TSE:197A) is 5.79%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Tauns Laboratories Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers